Medical abortion in the late first trimester: a systematic review.


Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
02 2019
Historique:
received: 16 07 2018
revised: 02 11 2018
accepted: 06 11 2018
pubmed: 18 11 2018
medline: 3 4 2020
entrez: 17 11 2018
Statut: ppublish

Résumé

To describe the efficacy, safety, and acceptability of medical abortion in the late first trimester. We searched PubMed and Cochrane databases for articles in any language that examined the success of medical abortion at gestational ages (>63 to≤84 days gestation). We sought articles that compared: medical abortion with surgical abortion at this gestational age, combination mifepristone and misoprostol and/or misoprostol alone); different dosages of misoprostol; different routes of misoprostol administration; frequency of dosing; and location of medical abortion (in health care facility vs. outpatient management). Our primary outcome was complete abortion. Data was independently abstracted by two authors, graded for evidence quality, and assessed for risk of bias. The search strategy returned 3384 articles, nine of which met inclusion criteria. Medical abortion, as compared with surgical abortion, was effective in the late first trimester (94.6% versus 97.9% complete abortion). A combined regimen of mifepristone and misoprostol was significantly more effective than misoprostol alone (90.4 versus 81.6% complete abortion). Complete abortion rates for all regimens investigated ranged from 78.6% to 94.6%. Success rates were higher with repeat dosing of misoprostol both in combination regimens and alone, and with vaginal compared with oral administration for repeat dosing. A limited body of evidence indicates a range of efficacy of medical abortion in the late first trimester and highlights the need for well-designed trials in this gestational age range. This review highlights the need for research focused on the late first trimester to strengthen the body of evidence. The available evidence is limited but offers reassurance that adverse events are rare for later first trimester abortion. Importantly, new research demonstrates that efficacy remains unchanged in the 10th gestational week regardless of whether the medication is taken in a facility or at a woman's home.

Identifiants

pubmed: 30444970
pii: S0010-7824(18)30486-4
doi: 10.1016/j.contraception.2018.11.002
pmc: PMC6367561
pii:
doi:

Substances chimiques

Abortifacient Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-86

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NICHD NIH HHS
ID : K12 HD085809
Pays : United States

Informations de copyright

Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Références

Contraception. 2013 Jan;87(1):26-37
pubmed: 22898359
Lancet. 2017 Nov 25;390(10110):2372-2381
pubmed: 28964589
Obstet Gynecol. 2008 Dec;112(6):1303-10
pubmed: 19037040
Health Technol Assess. 2009 Nov;13(53):1-124, iii-iv
pubmed: 19906334
Int J Gynaecol Obstet. 2016 Sep;134(3):268-71
pubmed: 27352735
Obstet Gynecol. 2012 Nov;120(5):1070-6
pubmed: 23090524
Contraception. 1996 Apr;53(4):244-6
pubmed: 8706443
Hum Reprod. 2002 Jan;17(1):92-8
pubmed: 11756368
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Contraception. 2010 Apr;81(4):323-7
pubmed: 20227549
Cochrane Database Syst Rev. 2011 Nov 09;(11):CD002855
pubmed: 22071804
Contraception. 2015 Sep;92(3):197-9
pubmed: 26118638
Aust N Z J Obstet Gynaecol. 2007 Jun;47(3):226-9
pubmed: 17550491
Contraception. 2014 Mar;89(3):181-6
pubmed: 24332431
BJOG. 2012 Jun;119(7):817-23
pubmed: 22432980
Am J Obstet Gynecol. 1997 Feb;176(2):431-7
pubmed: 9065194
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
BJOG. 2005 Aug;112(8):1102-8
pubmed: 16045525
Int J Gynaecol Obstet. 2010 Jun;109(3):213-5
pubmed: 20206352
Perspect Sex Reprod Health. 2017 Mar;49(1):17-27
pubmed: 28094905
Lancet. 2016 Jan 30;387(10017):462-74
pubmed: 26584737

Auteurs

Nathalie Kapp (N)

Ipas, P.O Box 9990, Chapel Hill, NC 27701. Electronic address: kappn@ipas.org.

Elisabeth Eckersberger (E)

Ipas, P.O Box 9990, Chapel Hill, NC 27701.

Antonella Lavelanet (A)

Department of Reproductive Health and Research and UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), World Health Organization, 20 Avenue Appia, CH-1211, Geneva 27, Switzerland.

Maria Isabel Rodriguez (MI)

Oregon Health & Science University, Department of Obstetrics & Gynecology, 3181 SW Sam Jackson Park Rd, Portland, OR 97239.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH